However, although promising results with NET inhibitors, such as DNase I and PAD4 inhibitors, have been reported in murine tumor models [17,19], no clinical trials in cancer patients have provided conclusive evidence of the efficacy of this strategy. This evidence concerns the gene PADI4 and neoplasm.